Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.43 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8523718 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2FDPSLMNAALDH1A1HSD17B10 | |
| SCHEMBL9575104 | 0.98 | LMNA (0.48) | SMN1; SMN2FDPSLMNAALDH1A1HSD17B10 | |
| SCHEMBL918621 | 0.98 | LMNA (0.48) | SMN1; SMN2FDPSLMNAALDH1A1HSD17B10 | |
| SCHEMBL3069042 | 0.98 | LMNA (0.48) | SMN1; SMN2FDPSLMNAALDH1A1HSD17B10 | |
| SCHEMBL1421830 | 0.98 | LMNA (0.48) | SMN1; SMN2FDPSLMNAALDH1A1HSD17B10 | |
| SCHEMBL8830314 | 0.98 | LMNA (0.48) | SMN1; SMN2FDPSLMNAALDH1A1HSD17B10 | |
| SCHEMBL3070711 | 0.98 | LMNA (0.48) | SMN1; SMN2FDPSLMNAALDH1A1HSD17B10 | |
| SCHEMBL4461494 | 0.98 | LMNA (0.48) | SMN1; SMN2FDPSLMNAALDH1A1HSD17B10 | |
| SCHEMBL221427 | 0.98 | LMNA (0.48) | SMN1; SMN2FDPSLMNAALDH1A1HSD17B10 | |
| SCHEMBL3069297 | 0.98 | LMNA (0.48) | SMN1; SMN2FDPSLMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4529528-A | Reacting an alkoxylated amine and a phosphite | MOBIL OIL CORPORATION (US) | 1985-07-16 | — | — | US | claimed |
| EP-3423554-B1 | LUBRICATING OIL COMPOSITION HAVING IMPROVED AIR RELEASE | LUBRIZOL CORP (US) | 2022-08-10 | — | — | EP | disclosed |
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-10-15 | — | — | US | disclosed |
| US-20200318027-A1 | Lubricating Oil Composition Having Improved Air Release | LUBRIZOL CORP (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3423554-A1 | LUBRICATING OIL COMPOSITION HAVING IMPROVED AIR RELEASE | The Lubrizol Corporation (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180110791-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2018-04-26 | — | — | US | disclosed |
| US-20170368194-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| WO-1991014043-A1 | COMPOSITIONS AND POLYMER FABRICS TREATED WITH THE SAME | THE LUBRIZOL CORPORATION (US) | 1991-09-19 | — | — | WO | disclosed |
| WO-1991014040-A1 | TREATED POLYMER FABRICS | THE LUBRIZOL CORPORATION (US) | 1991-09-19 | — | — | WO | disclosed |
| WO-1991009922-A1 | UNIVERSAL DRIVELINE FLUIDE | THE LUBRIZOL CORPORATION (US) | 1991-07-11 | — | — | WO | disclosed |
| US-4992184-A | Reaction product of arylsulfonic acid and (diol or amine) phosphite | MOBIL OIL CORPORATION (US) | 1991-02-12 | — | — | US | disclosed |
| US-4965002-A | Reaction product of alkoxylated amine and organic phosphize | ELCO CORPORATION (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0325977-A1 | Phosphite amine lubricant additives | THE ELCO CORPORATION (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4755311-A | Borated amine salt of dihydrocarbyl monothiophosphoric acid | THE LUBRIZOL CORPORATION (US) | 1988-07-05 | — | — | US | disclosed |
| US-4557845-A | FRICTION REDUCERS AND FUEL CONSUMPTION REDUCERS | MOBIL OIL CORPORATION (US) | 1985-12-10 | — | — | US | disclosed |
| US-4529528-A | Reacting an alkoxylated amine and a phosphite | MOBIL OIL CORPORATION (US) | 1985-07-16 | — | — | US | disclosed |
| US-4503002-A | CATIONIC SURFACTANTS | MONA INDUSTRIES, INC. (US) | 1985-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110791-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | SMN1; SMN2 1201/4885FDPS 2857/4885LMNA 3754/4885 |
| US-20170368194-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | SMN1; SMN2 422/4885FDPS 1007/4885LMNA 3937/4885 |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | SMN1; SMN2 1548/4885FDPS 1308/4885LMNA 3344/4885 |
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | SMN1; SMN2 1201/4885FDPS 2857/4885LMNA 3754/4885 |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | SMN1; SMN2 422/4885FDPS 1007/4885LMNA 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.